SEP 01, 2016 04:58 AM PDT

Drug Clears Toxic Protein Clusters in Alzheimer's Brain

WRITTEN BY: Xuan Pham
The beloved actor Gene Wilder died earlier this week from complications of Alzheimer’s disease. He was one of the tens of thousands of people who succumb to the disease, according to the Centers for Disease Control and Prevention.
 
But there’s some hope peeking through the grim statistics of this disease. Scientists recently announced highly promising results of a drug that purportedly can erase the toxic protein clumps in the Alzheimer brain.
 
Promising results for experimental Alzheimer drug | Image: pexels.com
The drug, known as aducanumab, targets the amyloid beta plaques in the brains of animal models, and now also in human clinical trials. As this drug progresses to Phase 3 to test efficacy in a larger group of patients, researchers are hopeful it will become the first drug to actually reverse Alzheimer pathology.
 
Amyloid plaque clumps (yellow) in the brainAlzheimer’s disease is pathologically defined with the presence of amyloid beta protein clumps in the brain. These are toxic to neurons and interfere with memory, cognition, and other normal functions of the brain. The CDC estimated 85,000 people died from Alzheimer’s disease in 2015; however, this number is believed to be an underestimate, as many deaths may not be correctly attributed to Alzheimer’s.
 
Aducanumab is an immune compound that appears to stimulate the body to remove the toxic amyloid clumps. In the latest study, scientists split 165 patients with mild Alzheimer’s disease into two groups: those who received aducanumab and those who received a placebo. This was done for 1 year, with the intent on demonstrating that the drug was safe to take.
 
Indeed, researchers found encouragement beyond safety. Through analyzing brain scans, the team found that patients treated aducanumab had less amyloid plaques than those treated with the placebo.
 
"After one year, you can see no red on the image, meaning the amyloid has almost completely
disappeared," said Dr. Roger Nitsch, a co-author of the study and the director of the Institute for Regenerative Medicine at the University of Zurich.
 
In addition, there was a direct correlation between dose and effect – the higher the dose, the greater the clearance of the toxic protein clumps. Notably, however, the higher dosages were also associated with more side effects.
 
Though the purpose of the study was to establish safety, the team did carry out some memory tests with some promising results. "We believe that's a hint of efficacy," study co-author Dr. Alfred Sandrock, a neurologist and an executive vice president at Biogen,
 
"We're encouraged that, there appeared to be a slowing of cognitive decline at a dose-dependent manner, and also a dose-dependent slowing in functional decline," said study co-author Dr. Stephen Salloway.
 
The next phase of the study will definitively answer whether aducanumab holds cognitive benefits for Alzheimer’s patients. A total of 2,700 patients are slated to be enrolled in this next phase, which will be an international effort involving North America, Europe, and Asia.
 
 
Additional sources: BBC, Nature News
About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
APR 16, 2018
Immunology
APR 16, 2018
Epstein-Barr Virus Raises Risk of 7 Diseases in Addition to Mono
The repercussions of an infection with Epstein-Barr virus (EBV) may not end with mononucleosis, “mono” or “the kissing disease.” Fi...
MAY 07, 2018
Clinical & Molecular DX
MAY 07, 2018
Sensory Processing Important for Autism Diagnosis
At least than a year old, an individual’s response to light can predict whether or not they’ll be diagnosed with autism later in life. In a new...
JUN 07, 2018
Genetics & Genomics
JUN 07, 2018
Easily Identifying Pregnancies at Risk for Premature Birth
Premature birth affects almost ten percent of pregnancies and is the leading cause of infant mortality in the US....
JUN 11, 2018
Clinical & Molecular DX
JUN 11, 2018
Nasal Brush Test for Asthma Diagnosis
Diagnosing mild-to-moderate asthma can be difficult to diagnose, especially when scientists need to rule out other respiratory disorders that have similar...
JUN 20, 2018
Genetics & Genomics
JUN 20, 2018
The Cause of a Rare Neurological Disease is Identified
In a recent study, scientists sequenced the genome to find the mutation behind a disorder that causes blindness and paralysis....
AUG 22, 2018
Clinical & Molecular DX
AUG 22, 2018
New Clinical Assay Useful For Urothelial Cancer
U.S. Food and Drug Administration (FDA) has now approved a pharmDx assay called ‘Dako PD-L1 IHC 22C3’ by Agilent Technologies Inc. for use in u...
Loading Comments...